

Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: March 29, 2021

Time: 1:00-4:00PM

Time	Topic	Description	Presenter(s)
1:00-1:10	<ul style="list-style-type: none">WelcomeAgenda and ObjectivesConflict of Interest (COI) Declarations	Inform members	Interim Chair
1:10-2:10	<ul style="list-style-type: none">Atezolizumab for locally advanced or metastatic non-small cell lung cancer (NSCLC) - addition of new dosing regimens (840mg every 2 weeks and 1680mg every 4 weeks)	Submission	Lead Presenter and Clinical Presenter Pharmacoeconomics Presenter
2:10-2:40	<ul style="list-style-type: none">Modernization of New Drug Funding Program (NDFP) breast cancer enrolment forms	Request for Advice	Lead Presenter Clinical Presenter
10-minute BREAK			
2:50-3:50	<ul style="list-style-type: none">Mitotane for treatment of inoperable adrenal cortical carcinoma of both functional and non-functional types	Submission	Lead Presenter and Clinical Presenter Pharmacoeconomics Presenter
3:50-4:00	<ul style="list-style-type: none">Closing remarks<ul style="list-style-type: none">Housekeeping ItemsUpdate from the Ministry	Inform members	Interim Chair Ministry of Health Representative